Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
about
Arsenic trioxide, a therapeutic agent for APL.Treatment of acute promyelocytic leukemia with arsenic trioxide: clinical and basic studies.Assessment of the involvement of oxidative stress and Mitogen-Activated Protein Kinase signaling pathways in the cytotoxic effects of arsenic trioxide and its combination with sulindac or its metabolites: sulindac sulfide and sulindac sulfone on hum
P2860
Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Pathologic, cytogenetic and mo ...... with arsenic trioxide (As2O3).
@ast
Pathologic, cytogenetic and mo ...... with arsenic trioxide (As2O3).
@en
type
label
Pathologic, cytogenetic and mo ...... with arsenic trioxide (As2O3).
@ast
Pathologic, cytogenetic and mo ...... with arsenic trioxide (As2O3).
@en
prefLabel
Pathologic, cytogenetic and mo ...... with arsenic trioxide (As2O3).
@ast
Pathologic, cytogenetic and mo ...... with arsenic trioxide (As2O3).
@en
P2093
P2860
P1433
P1476
Pathologic, cytogenetic and mo ...... with arsenic trioxide (As2O3).
@en
P2093
P2860
P2888
P304
P356
10.1038/MODPATHOL.3880174
P577
2000-09-01T00:00:00Z
P6179
1003016939